Life Science

Più recente

281 a 290 di 408
  • CIBA Vision fined for exerting price pressure on internet traders Accesso limitato

    Articolo

    Ultima consultazione: 01 October 2009 / Inviato: 01 October 2009

    The German Federal Cartel Office has imposed a fine of €11.5m for resale price maintenance.

  • Legal and ethical concerns in personalized medicine: a European perspective Accesso limitato

    Articolo

    Ultima consultazione: 28 September 2009 / Inviato: 28 September 2009

    Expectations in the integration of pharmacogenomics into clinical practice remain high in a number of therapeutic areas. This review focuses on the key legal and ethical issues concerning personalized medicine that have given rise to debate, law making and/or court decisions in Europe.

  • Pfizer’s fine shows the perils, and politics, of employees’ criminal activities Accesso limitato

    Articolo

    Ultima consultazione: 20 October 2009 / Inviato: 18 September 2009

    Pfizer have paid their fourth fine of the last ten years, to avoid criminal charges by the US authorities.

  • Winning strategies for IP protection and enforcement for the pharmaceutical industry in China Accesso limitato

    Articolo

    Ultima consultazione: 13 July 2009 / Inviato: 13 July 2009

    This article aims to help multinational pharmaceutical companies (MNCs) to craft a strategy to (a) protect their IP for inventions made in China, (b) avoid potential disputes on inventorship, including claims of rights by employees to inventions discovered during the course of their employment and for employee inventor remuneration, and (c) tackle generics and counterfeits in the market.

  • The Commission`s Final Report - but not the last word - on the pharmaceutical industry Accesso limitato

    Articolo

    Ultima consultazione: 21 January 2010 / Inviato: 09 July 2009

    The long awaited Final Report in the Sector Inquiry was published on 08 July 2009. Whilst the length of the Report exceeds that of the Preliminary Report, which obtained extensive publicity, the Final Report is more measured in its conclusions.

  • No obviousness where motivation to pursue obvious path is weak Accesso limitato

    Articolo

    Ultima consultazione: 21 January 2010 / Inviato: 03 July 2009

    In Generics (UK) v Daiichi the Court of Appeal held that, although a course of action was obvious, the skilled person`s motivation to pursue it to the point of making the invention was weak and accordingly the invention was not obvious. The court also said that an SPC may be granted for an enantiomer notwithstanding an earlier marketing authorisation for the racemate.

  • GlaxoSmithKline Spanish dual pricing case - an object restriction after all? Accesso limitato

    Articolo

    Ultima consultazione: 02 July 2009 / Inviato: 02 July 2009

    Advocate General Trstenjak has issued her opinion in the GlaxoSmithKline Spanish dual pricing cases.

  • Germany: Last word spoken in the DocMorris Saga Accesso limitato

    Articolo

    Ultima consultazione: 12 June 2009 / Inviato: 12 June 2009

    In its judgment of 19 May 2009 - the sixth act of the DocMorris saga - the European Court of Justice followed the opinion of Advocate General Bot and confirmed that the German Pharmacy Act is justified in restricting ownership and operation of pharmacies

  • The importance of being early Accesso limitato

    Articolo

    Ultima consultazione: 05 June 2009 / Inviato: 05 June 2009

    New case law demonstrates that the introduction, at trial, of fresh expert evidence is not a procedural irregularity if it is not challenged at the time.

  • Time barred damages claim in vitamins cartel likely to prompt earlier follow on actions Accesso limitato

    Articolo

    Ultima consultazione: 28 May 2009 / Inviato: 28 May 2009

    The Court of Appeal has dealt a blow to claimants who were seeking damages arising from the vitamins cartel.

281 a 290 di 408